Arch Oncology
St Louis
About Arch Oncology
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $250.4M
- Funding stage: Late Stage Venture
- Last round: Series C (Apr 2021)
- Website: archoncology.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/arch-oncology-93476 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.